Uncategorized
ONL Therapeutics closes $4.25 million in Series A funding
ONL Therapeutics has closed $4.25 million in Series A funding for preclinical development of its lead therapeutic candidate, ONL1204, designed to treat retinal detachment, according to a company press release.The funding, which came from investors including Novartis, the University of Michigan’s Michigan Investment in New Technology Startups program, Capital Community Angels, Invest Michigan, Biosciences Research & Commercialization Center and Hestia Investments, will be combined with a $1 million grant from the National Eye Institute.